An open-label, non-randomized, prospective study assessing intralesional PV-10 for the treatment of in-transit melanoma metastases
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
Price : $35 *
At a glance
- Drugs Rose bengal sodium (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- 25 Apr 2018 New trial record.
- 19 Apr 2018 Results published in the Provectus Biopharmaceuticals media release.
- 01 Mar 2018 Results published in the Journal of Surgical Oncology.